Active, not recruitingPHASE1, PHASE2NCT03294083
A Study of Recombinant Vaccinia Virus in Combination With Cemiplimab for Renal Cell Carcinoma
Studying Clear cell renal carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SillaJen, Inc.
- Intervention
- Pexastimogene Devacirepvec (Pexa-Vec)(biological)
- Enrollment
- 89 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2018 – 2023
Study locations (18)
- Site 2644 University of California, Irvine, Irvine, California, United States
- Site 2641 University of Miami, Miami, Florida, United States
- Site 2643 Washington University, St Louis, Missouri, United States
- Site 2646 The Ohio State University, Columbus, Ohio, United States
- Site 2632 Flinders Medical Centre, Bedford Park, Australia
- Site 2612 Kyungpook National University Chilgok Hospital, Daegu, South Korea
- Site 2616 Chungnam National University Hospital, Daejeon, South Korea
- Site 2618 Chonnam National University Hwasun Hospital, Gwangju, South Korea
- Site 2622 Gachon University Gil Medical Center, Incheon, South Korea
- Site 2613 Dong-A University Hospital, Pusan, South Korea
- Site 2619 Pusan National University Hospital, Pusan, South Korea
- Site 2617 CHA University, CHA Bundang Medical Center, Seongnam, South Korea
- Site 2620 Seoul National University Bundang Hospital, Seongnam-si, South Korea
- Site 2615 Korea University Anam Hospital, Seoul, South Korea
- Site 2610 Severance Hospital, Yonsei University Health System, Seoul, South Korea
- +3 more locations on ClinicalTrials.gov
Collaborators
Regeneron Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03294083 on ClinicalTrials.govOther trials for Clear cell renal carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07128680Immunotherapy (Nivolumab and Ipilimumab) With and Without a Live Biotherapeutic Product (EXL01) for the Treatment of Metastatic Renal Cell CancerCity of Hope Medical Center
- RECRUITINGPHASE2NCT06863311Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCCKarie Runcie
- RECRUITINGPHASE2NCT07397611Pre-NEOSHIFT-RCC: Neoadjuvant HIF-Inhibitor Immunotherapy in RCCDana-Farber Cancer Institute
- RECRUITINGPHASE2NCT07469683An Open-label, Randomized Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of the Combination Therapy of SLC-3010 and Axitinib Compared to Axitinib Monotherapy as a Second-line Treatment for Locally Advanced or Metastatic Clear Cell Renal Cell CarcinomaYonsei University
- RECRUITINGPHASE2NCT07188896A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)Brian Rini
- RECRUITINGPHASE1, PHASE2NCT07227415A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerPfizer
- RECRUITINGPHASE1, PHASE2NCT07551349Dual-target CD70/CAIX CAR-NK Cells for Advanced Clear Cell Renal Cell CarcinomaBeijing Biotech
- RECRUITINGPHASE2NCT07223541Cemiplimab or Cemiplimab and Fianlimab After Stereotactic Body Radiotherapy in Clear Cell Renal Cell CarcinomaUniversity of Oklahoma